Pyrimidinone-containing 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors

A compound represented by Formula I or a pharmaceutically acceptable salt, or ester thereof:

• wherein
• M is S, SO, SO2, O or NR7;
• R1 and R2 are each independently selected from the group consisting of:
• 1) Hydrogen;
• 2) Optionally substituted —C1-C8 alkyl;
• 3) Optionally substituted —C2-C8 alkenyl;
• 4) Optionally substituted —C2-C8 alkynyl;
• 5) Optionally substituted —C3-C8 cycloalkyl;
• 6) Optionally substituted aryl;
• 7) Optionally substituted arylalkyl;
• 8) Optionally substituted 3- to 8-membered heterocycloalkyl;
• 9) Optionally substituted heteroaryl;
• and
• 10) Optionally substituted heteroarylalkyl;
• R3, R4, R5, and R6 are each independently selected from the group consisting of hydrogen, halogen, —CN, —OR9, —SR9, —C(O)R7, —C(O)OR7, —NR7R8, —C(O)NR7R8, optionally substituted —C1-C8 alkyl, optionally substituted aryl, and optionally substituted heteroaryl;
• alternatively, R5 and R6 are taken together with the carbon atoms to which they are attached to form an optionally substituted carbocyclic or heterocyclic ring;
• alternatively, R4 and R5 are taken together with the carbon atoms to which they are attached to form an optionally substituted carbocyclic or heterocyclic ring;
• alternatively, R3 and R4 are taken together with the carbon atoms to which they are attached to form an optionally substituted carbocyclic or heterocyclic ring;
• each R7 and R8 is independently selected from the group consisting of:
• 1) Hydrogen;
• 2) Optionally substituted —C1-C8 alkyl;
• 3) Optionally substituted —C2-C8 alkenyl;
• 4) Optionally substituted —C2-C8 alkynyl;
• 5) Optionally substituted —C3-C8 cycloalkyl;
• 6) Optionally substituted 3- to 8-membered heterocycloalkyl;
• 7) Optionally substituted aryl;
• 8) Optionally substituted arylalkyl;
• 9) Optionally substituted heteroaryl;
• and
• 10) Optionally substituted heteroarylalkyl;
• alternatively, R7 and R8 are taken together with the nitrogen atom to which they are attached to form an optionally substituted heterocyclic ring;
• R9 is selected from the group consisting of:
• 1) Hydrogen;
• 2) Optionally substituted —C1-C8 alkyl;
• 3) Optionally substituted —C2-C8 alkenyl;
• 4) Optionally substituted —C2-C8 alkynyl;
• 5) Optionally substituted —C3-C8 cycloalkyl;
• 6) Optionally substituted 3- to 8-membered heterocycloalkyl;
• 7) Optionally substituted aryl;
• 8) Optionally substituted arylalkyl;
• 9) Optionally substituted heteroaryl;
• 10) Optionally substituted heteroarylalkyl;
• 11) —C(O)R11;
• 12) —C(O)NR11R12;
• 13) —C(O)OR11;
• 14) —P(O)(OR13)2;
• and
• 15) —P(O)(OR13)(NR11R12);
• each R11 and R12 is independently selected from the group consisting of:
• 1) Hydrogen;
• 2) Optionally substituted —C1-C8 alkyl;
• 3) Optionally substituted —C2-C8 alkenyl;
• 4) Optionally substituted —C2-C8 alkynyl;
• 5) Optionally substituted —C3-C8 cycloalkyl;
• 6) Optionally substituted 3- to 8-membered heterocycloalkyl;
• 7) Optionally substituted aryl;
• 8) Optionally substituted arylalkyl;
• 9) Optionally substituted heteroaryl;
• and
• 10) Optionally substituted heteroarylalkyl;
• and R13 is hydrogen, optionally substituted —C1-C8 alkyl, or Na+.